Report Update Mar 1, 2026

Croatia - Medicaments Containing Insulin But not Antibiotics in Measured Doses - Market Analysis, Forecast, Size, Trends and Insights

Single report

Sent by email within 24h (Mon-Fri)

$599 Basic Edition

$2095 Professional Edition

What's the difference?

Subscription

Online access and download

from $350/month

Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.

View Pricing

Croatia: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2026

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Croatia

The Croatian prophylactic medicaments containing insulin market skyrocketed to $X in 2025, jumping by X% against the previous year. This figure reflects the total revenues of producers and importers (excluding logistics costs, retail marketing costs, and retailers' margins, which will be included in the final consumer price). In general, the total consumption indicated a prominent increase from 2012 to 2025: its value increased at an average annual rate of X% over the last twelve-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2025 figures, consumption increased by X% against 2021 indices. Prophylactic medicaments containing insulin consumption peaked in 2025 and is expected to retain growth in the immediate term.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports from Croatia

In 2025, overseas shipments of medicaments containing insulin but not antibiotics in measured doses increased by X% to X kg for the first time since 2021, thus ending a two-year declining trend. Over the period under review, exports showed significant growth. The growth pace was the most rapid in 2015 with an increase of X% against the previous year. The exports peaked in 2025 and are likely to continue growth in the near future.

In value terms, prophylactic medicaments containing insulin exports skyrocketed to $X in 2025. Overall, exports showed a significant expansion. The growth pace was the most rapid in 2016 when exports increased by X%. Over the period under review, the exports reached the maximum in 2025 and are expected to retain growth in years to come.

Exports by Country

Lithuania (X kg), Denmark (X kg) and the Netherlands (X kg) were the main destinations of prophylactic medicaments containing insulin exports from Croatia, together comprising X% of total exports.

From 2014 to 2025, the most notable rate of growth in terms of shipments, amongst the main countries of destination, was attained by the Netherlands (with a CAGR of X%), while the other leaders experienced more modest paces of growth.

In value terms, Denmark ($X) emerged as the key foreign market for medicaments containing insulin but not antibiotics in measured doses exports from Croatia, comprising X% of total exports. The second position in the ranking was held by the Netherlands ($X), with a X% share of total exports. It was followed by Lithuania, with an X% share.

From 2014 to 2025, the average annual rate of growth in terms of value to Denmark totaled X%. Exports to the other major destinations recorded the following average annual rates of exports growth: the Netherlands (X% per year) and Lithuania (X% per year).

Export Prices by Country

In 2025, the average prophylactic medicaments containing insulin export price amounted to $X per ton, shrinking by X% against the previous year. Overall, the export price saw a relatively flat trend pattern. The growth pace was the most rapid in 2023 an increase of X%. As a result, the export price reached the peak level of $X per ton, and then shrank sharply in the following year.

Prices varied noticeably by country of destination: amid the top suppliers, the country with the highest price was the Czech Republic ($X,333 per ton), while the average price for exports to Lithuania ($X per ton) was amongst the lowest.

From 2014 to 2025, the most notable rate of growth in terms of prices was recorded for supplies to Hungary (X%), while the prices for the other major destinations experienced more modest paces of growth.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports into Croatia

For the third consecutive year, Croatia recorded growth in purchases abroad of medicaments containing insulin but not antibiotics in measured doses, which increased by X% to X tons in 2025. Over the period under review, total imports indicated a remarkable increase from 2012 to 2025: its volume increased at an average annual rate of X% over the last twelve-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2025 figures, imports increased by X% against 2021 indices. The pace of growth appeared the most rapid in 2013 when imports increased by X% against the previous year. Imports peaked in 2025 and are expected to retain growth in the near future.

In value terms, prophylactic medicaments containing insulin imports surged to $X in 2025. In general, imports posted a buoyant expansion. The most prominent rate of growth was recorded in 2013 when imports increased by X% against the previous year. Over the period under review, imports reached the maximum in 2025 and are expected to retain growth in the near future.

Imports by Country

In 2025, Denmark (X tons) constituted the largest prophylactic medicaments containing insulin supplier to Croatia, accounting for a X% share of total imports. Moreover, prophylactic medicaments containing insulin imports from Denmark exceeded the figures recorded by the second-largest supplier, Slovenia (X tons), eightfold.

From 2012 to 2025, the average annual rate of growth in terms of volume from Denmark stood at X%. The remaining supplying countries recorded the following average annual rates of imports growth: Slovenia (X% per year) and Germany (X% per year).

In value terms, Denmark ($X) constituted the largest supplier of medicaments containing insulin but not antibiotics in measured doses to Croatia, comprising X% of total imports. The second position in the ranking was held by Slovenia ($X), with an X% share of total imports.

From 2012 to 2025, the average annual growth rate of value from Denmark stood at X%. The remaining supplying countries recorded the following average annual rates of imports growth: Slovenia (X% per year) and Germany (X% per year).

Import Prices by Country

In 2025, the average prophylactic medicaments containing insulin import price amounted to $X per ton, picking up by X% against the previous year. In general, import price indicated noticeable growth from 2012 to 2025: its price increased at an average annual rate of X% over the last twelve years. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2025 figures, prophylactic medicaments containing insulin import price increased by X% against 2019 indices. The most prominent rate of growth was recorded in 2021 an increase of X% against the previous year. Over the period under review, average import prices hit record highs in 2025 and is expected to retain growth in the immediate term.

Average prices varied noticeably amongst the major supplying countries. In 2025, amid the top importers, the country with the highest price was Slovenia ($X per ton), while the price for Germany ($X per ton) was amongst the lowest.

From 2012 to 2025, the most notable rate of growth in terms of prices was attained by Hungary (X%), while the prices for the other major suppliers experienced more modest paces of growth.

Frequently Asked Questions (FAQ) :

What are the largest markets for medicaments containing insulin but not antibiotics in measured doses in the world?

The countries with the highest volumes of consumption in 2024 were Denmark, India and Brazil, together comprising 43% of global consumption.

What are the largest producers of medicaments containing insulin but not antibiotics in measured doses in the world?

The countries with the highest volumes of production in 2024 were India, Denmark and France, with a combined 65% share of global production. Ireland, Brazil, Italy and China lagged somewhat behind, together accounting for a further 32%.

What are the leading suppliers of medicaments containing insulin but not antibiotics in measured doses to Croatia?

In value terms, Denmark constituted the largest supplier of medicaments containing insulin but not antibiotics in measured doses to Croatia, comprising 83% of total imports. The second position in the ranking was held by Slovenia, with an 11% share of total imports.

What are the leading importers of medicaments containing insulin but not antibiotics in measured doses from Croatia?

In value terms, Denmark emerged as the key foreign market for medicaments containing insulin but not antibiotics in measured doses exports from Croatia, comprising 54% of total exports. The second position in the ranking was held by the Netherlands, with a 20% share of total exports. It was followed by Lithuania, with an 18% share.

What is the average export price for medicaments containing insulin but not antibiotics in measured doses in Croatia?

The average prophylactic medicaments containing insulin export price stood at $682,507 per ton in 2024, shrinking by -20.9% against the previous year. Overall, the export price showed a relatively flat trend pattern. The pace of growth was the most pronounced in 2023 an increase of 61%. As a result, the export price reached the peak level of $862,398 per ton, and then contracted remarkably in the following year.

What is the average import price for medicaments containing insulin but not antibiotics in measured doses in Croatia?

In 2024, the average prophylactic medicaments containing insulin import price amounted to $391,789 per ton, rising by 4.1% against the previous year. Over the period under review, import price indicated tangible growth from 2012 to 2024: its price increased at an average annual rate of +2.7% over the last twelve years. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2024 figures, prophylactic medicaments containing insulin import price increased by +54.5% against 2019 indices. The most prominent rate of growth was recorded in 2021 when the average import price increased by 35%. The import price peaked in 2024 and is expected to retain growth in the near future.

This report provides a comprehensive view of the prophylactic medicaments containing insulin industry in Croatia, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.

Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the prophylactic medicaments containing insulin landscape in Croatia.

Key findings

Domestic demand is shaped by both household and industrial usage, with trade flows linking local supply to imports and exports.
Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
Supply depends on input availability and production efficiency, creating a distinct national cost curve.
Market concentration varies by segment, creating different competitive landscapes and entry barriers.
The 2035 outlook highlights where capacity investment and demand growth are most aligned within the country.

Report scope

The report combines market sizing with trade intelligence and price analytics for Croatia. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.

Market size and growth in value and volume terms
Consumption structure by end-use segments
Production capacity, output, and cost dynamics
Trade flows, exporters, importers, and balances
Price benchmarks, unit values, and margin signals
Competitive context and market entry conditions

Product coverage

Prodcom 21201260 - Medicaments containing insulin but not antibiotics, for therapeutic or prophylactic uses, put up in measured doses or for retail sale

Country coverage

Croatia

Country profile and benchmarks

This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for Croatia. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.

Methodology

The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.

International trade data (exports, imports, and mirror statistics)
National production and consumption statistics
Company-level information from financial filings and public releases
Price series and unit value benchmarks
Analyst review, outlier checks, and time-series validation

All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.

Forecasts to 2035

The forecast horizon extends to 2035 and is based on a structured model that links prophylactic medicaments containing insulin demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in Croatia.

Historical baseline: 2012-2025
Forecast horizon: 2026-2035
Scenario-based sensitivity to income growth, substitution, and regulation
Capacity and investment outlook for major producing companies

Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.

Price analysis and trade dynamics

Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.

Price benchmarks by country and sub-region
Export and import unit value trends
Seasonality and calendar effects in trade flows
Price outlook to 2035 under baseline assumptions

Profiles of market participants

Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.

Business focus and production capabilities
Geographic reach and distribution networks
Cost structure and pricing strategy indicators
Compliance, certification, and sustainability context

How to use this report

Quantify domestic demand and identify the most attractive segments
Evaluate export opportunities and prioritize target destinations
Track price dynamics and protect margins
Benchmark performance against leading competitors
Build evidence-based forecasts for investment decisions

This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of prophylactic medicaments containing insulin dynamics in Croatia.

FAQ

What is included in the prophylactic medicaments containing insulin market in Croatia?

The market size aggregates consumption and trade data, presented in both value and volume terms.

How are the forecasts to 2035 built?

The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.

Does the report cover prices and margins?

Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.

Which benchmarks are included?

The report benchmarks market size, trade balance, prices, and per-capita indicators for Croatia.

Can this report support market entry decisions?

Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.

1. INTRODUCTION

Making Data-Driven Decisions to Grow Your Business
1. REPORT DESCRIPTION
2. RESEARCH METHODOLOGY AND THE AI PLATFORM
3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
4. GLOSSARY AND SPECIFIC TERMS
2. EXECUTIVE SUMMARY

A Quick Overview of Market Performance
1. KEY FINDINGS
2. MARKET TRENDSThis Chapter is Available Only for the Professional EditionPRO
3. MARKET OVERVIEW

Understanding the Current State of The Market and its Prospects
1. MARKET SIZE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. MARKET STRUCTURE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
3. TRADE BALANCE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
4. PER CAPITA CONSUMPTION: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
5. MARKET FORECAST TO 2035
4. MOST PROMISING PRODUCTS FOR DIVERSIFICATION

Finding New Products to Diversify Your Business
- This Chapter is Available Only for the Professional EditionPRO
1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
2. BEST-SELLING PRODUCTS
3. MOST CONSUMED PRODUCTS
4. MOST TRADED PRODUCTS
5. MOST PROFITABLE PRODUCTS FOR EXPORTS
5. MOST PROMISING SUPPLYING COUNTRIES

Choosing the Best Countries to Establish Your Sustainable Supply Chain
- This Chapter is Available Only for the Professional EditionPRO
1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
2. TOP PRODUCING COUNTRIES
3. TOP EXPORTING COUNTRIES
4. LOW-COST EXPORTING COUNTRIES
6. MOST PROMISING OVERSEAS MARKETS

Choosing the Best Countries to Boost Your Export
- This Chapter is Available Only for the Professional EditionPRO
1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
2. TOP CONSUMING MARKETS
3. UNSATURATED MARKETS
4. TOP IMPORTING MARKETS
5. MOST PROFITABLE MARKETS
7. PRODUCTION

The Latest Trends and Insights into The Industry
1. PRODUCTION VOLUME AND VALUE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
8. IMPORTS

The Largest Import Supplying Countries
1. IMPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. IMPORTS BY COUNTRY: HISTORICAL DATA (2012–2025)
3. IMPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025)
9. EXPORTS

The Largest Destinations for Exports
1. EXPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. EXPORTS BY COUNTRY: HISTORICAL DATA (2012–2025)
3. EXPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025)
10. PROFILES OF MAJOR PRODUCERS

The Largest Producers on The Market and Their Profiles
- This Chapter is Available Only for the Professional EditionPRO
LIST OF TABLES
1. Key Findings In 2025
2. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
3. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
4. Per Capita Consumption: Historical Data (2012–2025) and Forecast (2026–2035)
5. Imports, In Physical Terms, By Country, 2012–2025
6. Imports, In Value Terms, By Country, 2012–2025
7. Import Prices, By Country, 2012–2025
8. Exports, In Physical Terms, By Country, 2012–2025
9. Exports, In Value Terms, By Country, 2012–2025
10. Export Prices, By Country, 2012–2025
LIST OF FIGURES
1. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
2. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
3. Market Structure – Domestic Supply vs. Imports, in Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
4. Market Structure – Domestic Supply vs. Imports, in Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
5. Trade Balance, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
6. Trade Balance, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
7. Per Capita Consumption: Historical Data (2012–2025) and Forecast (2026–2035)
8. Market Volume Forecast to 2035
9. Market Value Forecast to 2035
10. Market Size and Growth, By Product
11. Average Per Capita Consumption, By Product
12. Exports and Growth, By Product
13. Export Prices and Growth, By Product
14. Production Volume and Growth
15. Exports and Growth
16. Export Prices and Growth
17. Market Size and Growth
18. Per Capita Consumption
19. Imports and Growth
20. Import Prices
21. Production, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
22. Production, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
23. Imports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
24. Imports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
25. Imports, In Physical Terms, By Country, 2025
26. Imports, In Physical Terms, By Country, 2012–2025
27. Imports, In Value Terms, By Country, 2012–2025
28. Import Prices, By Country, 2012–2025
29. Exports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
30. Exports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
31. Exports, In Physical Terms, By Country, 2025
32. Exports, In Physical Terms, By Country, 2012–2025
33. Exports, In Value Terms, By Country, 2012–2025
34. Export Prices, By Country, 2012–2025

Mar 19, 2026

Branded Pharma Sector Reports Mixed Q4 2025 Results

An analysis of Q4 2025 earnings reveals the branded pharmaceutical sector posted mixed results, missing revenue estimates. While Eli Lilly and Zoetis outperformed, the sector faces patent cliffs and regulatory pressures.

Mar 18, 2026

Weight Loss Drug Market: Eli Lilly Leads, Viking Therapeutics Emerges as Key Competitor

Analysis of the high-growth weight loss drug market, detailing Eli Lilly's leadership, the race for oral treatments, and Viking Therapeutics' competitive potential based on recent positive trial data.

Mar 3, 2026

Wall Street Analysts Adjust Ratings on Block, Palo Alto Networks, MongoDB, and Others

Overview of recent analyst rating adjustments on several companies, detailing key upgrades and downgrades based on earnings, guidance, and market conditions.

Feb 5, 2026

Eli Lilly Projects 2026 Profit Above Estimates Fueled by Obesity Drug Demand

Eli Lilly projects its 2026 profit will exceed analyst estimates, fueled by surging demand for obesity treatments like Zepbound and the upcoming launch of an oral weight-loss pill.

Jan 31, 2026

Eli Lilly Building $3.5 Billion Pharmaceutical Plant in Pennsylvania for Injectable Drugs

Eli Lilly is constructing a $3.5B plant in Pennsylvania to boost production of injectable obesity and diabetes drugs like retatrutide, part of its major domestic expansion.

Jan 7, 2026

Healthcare Stocks: Sector Gains 19.9% with AbbVie, Insulet, Cencora Highlighted

Healthcare sector outperforms S&P 500 by 9.1 percentage points with 19.9% gains. Analysis identifies three resilient stocks—AbbVie, Insulet, and Cencora—amid innovation and regulatory caution.

G2 reviews

Teams rate IndexBox on G2

Verified reviewers highlight faster qualification, clearer collaboration, and stronger bid readiness.

High Performer

Regional Grid

High Performer Small-Business

Grid Report

Leader Small-Business

Grid Report

High Performer Mid-Market

Grid Report

Leader

Grid Report

Users Love Us

Milestone badge

★ ★ ★ ★ ★

5/5

Great for Market Insights and Analysis

“IndexBox is a solid source for trade and industrial market data — what I like best about it is how it aggregates official statistics.”